We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Bausch Lomb Corp
2 own
2 watching
Current Price
$18.51
$0
(0%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
6,478.51M
52-Week High
19.96
52-Week Low
12.2
Average Volume
0M
Dividend Yield
--
P/E Ratio
--
Market Capitalization6,478.51M52-Week High19.9652-Week Low12.2Average Volume0MDividend Yield--P/E Ratio--What does the Bausch Lomb Corp do?
Bausch + Lomb is a leading global eye health company dedicated to protecting and enhancing the gift of sight for millions of people around the world—from the moment of birth through every phase of life. Our mission is simple, yet powerful: helping you see better, to live better. Our comprehensive portfolio of over 400 products is fully integrated and built to serve our customers across the full spectrum of their eye health needs throughout their lives. Our iconic brand is built on the deep trust and loyalty of our customers established over our nearly 170-year history. We have a significant global research, development, manufacturing and commercial footprint of approximately 12,500 employees and a presence in approximately 100 countries, extending our reach to billions of potential customers across the globe. We have long been associated with many of the most significant advances in eye health, and we believe we are well positioned to continue leading the advancement of eye health in the future. Our iconic and enduring brands are among the most recognized and most trusted in the industry. Since our beginnings in 1853 as an optical goods shop in Rochester, New York, we have remained focused on advancing eye health for people all over the world. Among our many innovations over the years, we introduced the first optical glass in the United States, the lenses used on cameras to take the first satellite picture of the moon, and the first mass-produced soft contact lens in 1971. As part of our longstanding commitment to eye care professionals and the patients they serve, we invest in physician training, patient and customer education, disease prevention and other initiatives through both traditional and digital platforms to continue to advance eye health. As illustrated in the table below, a recent survey of over 200 respondents globally conducted by TechSci Research indicated that Bausch + Lomb had the highest brand awareness among certain key competitors. As a result of this legacy, we believe our brand is synonymous with eye health among patients, consumers and professionals around the world. --- Our brands are leaders within their respective segments and collectively represent a leading portfolio of trusted assets that we believe makes us the eye health brand of choice. With one of the broadest product portfolios in the market, we are designed to address numerous large, underserved and growing markets with significant commercial potential. Our widespread complementary portfolio spans vision care, consumer health care, ophthalmic pharmaceuticals and surgical. We have well-established lines of contact lenses, intraocular lenses (“IOL”), medical devices, surgical systems, vitamin and mineral supplements, lens care products, prescription eye-medications and over-the-counter (“OTC”) eye health consumer products. We believe the breadth of our eye health portfolio is unmatched in the industry and uniquely positions us to compete in all areas of the eye health market. --- Our global brand, scale and infrastructure enable us to sell our products and support our customers in eye health markets globally, and we are well-positioned to capitalize on this opportunity. Our footprint is bolstered by a global commercial team of approximately 4,200 employees. In addition, we have 24 facilities in 10 countries that support the quality, reliability and capacity needs of our global manufacturing operations, supply chain, customer service and technical support, and that we believe will facilitate the development and distribution of our pipeline products. We have a long history of leading the eye health market with ground-breaking innovations. Our research and development (“R&D”) personnel partner closely with our quality, manufacturing and commercial groups, and as a result of these collaborations, we have developed the world’s first soft contact lens, introduced one of the first contact lens cleaning products, introduced the first silicone hydrogel contact lens and introduced a unique patent-protected ocular vitamin to the market. Since 2017, we have introduced more than 260 new products in approximately 60 countries. Our team of approximately 850 dedicated R&D employees is focused on advancing our pipeline and identifying new product opportunities that address unmet and evolving needs of eye care professionals, patients and consumers. Our culture of innovation engages our R&D, supply chain and commercial teams at every phase of product development, prioritizing customer needs and actively seeking external innovation to design, develop and advance creative, ethical eye health products across our portfolio, which allows us to address the changing needs of our consumers and patients. We believe we have a significant innovation opportunity today, with a substantial pipeline of over 100 projects in various stages of pre-clinical and clinical development, including new contact lenses, contact lenses to slow myopia progress in children, prescription medications for myopia, next-generation cataract equipment, premium IOLs, investigational treatments for dry-eye and preservative free formulations of a range of eye drops, among others, that are designed to grow our portfolio and accelerate future growth. The markets in which we operate are large and growing. We estimate that the global eye health market was nearly $50 billion in revenue in 2019, which we believe will grow at a compounded annual growth rate of nearly 4% through 2025. Global Market Revenue 2019-2025E 2019 2025E CAGR (in billions) Global Ophthalmic Pharmaceuticals $ 25.7 $ 32.1 3.8 % Global Ophthalmic Surgical 8.4 11.3 5.0 % Global Vision Care 15.7 19.7 3.9 % $ 49.8 $ 63.2 4.0 % • Global ophthalmic pharmaceuticals market size includes sales from products for the treatment of wet age-related macular degeneration (“AMD”), dry AMD, dry eye, glaucoma, diabetic macular edema (“DME”), conjunctivitis, ocular pain and inflammation, other corneal and external eye disorders, other retinal disorders, uveitis, and inherited retinal disorders, and other ophthalmology treatments. • Global ophthalmic surgical market size includes sales from capital equipment, procedure fees, instruments and implantables. • Global vision care market size includes sales from contact lenses, lens care solutions, and off-the-shelf eye care products, including sales from eye drops and eye vitamins. Growing demand for eye health products is being driven by significant and durable tailwinds, including an aging global population, greater time spent in front of computer and mobile screens, the rapid growth of the middle class in emerging markets, increasing global prevalence of diabetes, significant unmet medical need, particularly with respect to myopia, dry eye and AMD, and greater patient and consumer awareness. As such, we believe that the global incidence of major eye conditions will grow at a compounded annual growth rate of approximately 3% from 2019 to 2025. Global Eye Conditions 2019-2025E 2019 2025E CAGR (in millions) Myopia + Hyperopia 3,373 4,355 4.4 % Presbyopia 2,067 2,358 2.2 % Cataract (60+ population) 1,018 1,215 3.0 % Retina 371 435 2.7 % Glaucoma 139 162 2.6 % Dry Eye 730 783 1.2 % 7,698 9,308 3.2 % --- We believe that we are uniquely positioned in the global eye health market, with a diverse and comprehensive portfolio and pipeline that address major categories of eye conditions. --- Our revenues for the years ended December 31, 2021, 2020, and 2019 were $3,765 million, $3,412 million and $3,778 million, respectively. Our product portfolio consists of over 400 products, which fall into three operating and reportable segments: (i) Vision Care/Consumer Health Care, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical. Segment revenues and profit for the years ended December 31, 2021, 2020 and 2019 were as follows: Years Ended December 31, 2021 2020 2019 Amount Percent Amount Percent Amount Percent (amounts in millions) Segment revenues: Vision Care/Consumer Health Care $ 2,343 62 % $ 2,109 62 % $ 2,221 59 % Ophthalmic Pharmaceuticals 704 19 % 726 21 % 859 23 % Surgical 718 19 % 577 17 % 698 18 % Total revenues $ 3,765 100 % $ 3,412 100 % $ 3,778 100 % Segment profit: Vision Care/Consumer Health Care $ 587 62 % $ 579 64 % $ 606 55 % Ophthalmic Pharmaceuticals 290 30 % 302 34 % 412 38 % Surgical 75 8 % 18 2 % 75 7 % Segment profit is based on operating income after the elimination of intercompany transactions. Certain costs, such as amortization of intangible assets, asset impairments, in-process research and development costs, restructuring and integration costs, acquisition-related contingent consideration costs and other expense (income), net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance. Our business was founded in 1853 and incorporated in the State of New York in 1908 (“Old Bausch + Lomb”). Our executive offices are located at 520 Applewood Crescent, Vaughan, Ontario, Canada.
Read More
How much money does Bausch Lomb Corp make?
News & Events about Bausch Lomb Corp.
Business Wire
1month ago
Bausch + Lomb Corporation (NYSE/TSX: BLCO) (Bausch + Lomb or the Company), a leading global eye health company dedicated to helping people see better to live better, announced the appointments of Bob Bailey as executive vice president (EVP) and Chief Legal Officer and Andrew Stewart as president...
Zolmax
3 months ago
Bausch + Lomb Co. (NYSE:BLCO Get Rating) has received an average recommendation of Moderate Buy from the fifteen brokerages that are presently covering the company, MarketBeat reports. Four equities research analysts have rated the stock with a hold recommendation and ten have ...
Ticker Report
3 months ago
Bausch + Lomb (NYSE:BLCO Get Rating) had its price target increased by analysts at Deutsche Bank Aktiengesellschaft from $16.00 to $18.00 in a report issued on Thursday, The Fly reports. Deutsche Bank Aktiengesellschafts price target indicates a potential downside of 1.80% from the ...
Business Wire
4 months ago
Bausch + Lomb Corporation (NYSE/TSX: BLCO) (Bausch + Lomb), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2022 financial results on Wednesday, Feb. 22, 2023. Bausch + Lomb will host a conference call and live...
Business Wire
5 months ago
Bausch + Lomb Corporation, (NYSE/TSX: BLCO) (Bausch + Lomb or the Company), a leading global eye health company dedicated to helping people see better to live better, has published a company update presentation designed to complement remarks that will be provided by management at 3:00 p.m. PT (6:00...
Frequently Asked Questions
Frequently Asked Questions
What is Bausch Lomb Corp share price today?
Can Indians buy Bausch Lomb Corp shares?
How can I buy Bausch Lomb Corp shares from India?
Can Fractional shares of Bausch Lomb Corp be purchased?
What are the documents required to start investing in Bausch Lomb Corp stocks?
What is today’s traded volume of Bausch Lomb Corp?
What is today’s market capitalisation of Bausch Lomb Corp?
What is the 52-Week High and Low Range of Bausch Lomb Corp?
What percentage is Bausch Lomb Corp down from its 52-Week High?
What percentage is Bausch Lomb Corp up from its 52-Week Low?
Current Price
$18.51
$0
(0%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.